US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Advanced Cancer · Advanced Solid Tumors · TCRT
Alaunos Therapeutics
Alaunos Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
8030 El Rio St, Houston, Texas 77054, US HQ
10 Employees
Public company Type
TCRT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 8030 El Rio St, Houston, Texas 77054, US
- Employees
- 10
- Programs
- 34
- Drugs
- 12
- Patents
- 0
Alaunos Therapeutics pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alaunos Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
Development asset linked to Alaunos Therapeutics in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Alaunos Therapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Alaunos Therapeutics in public FDA and regional records.
-
Development asset linked to Alaunos Therapeutics in public FDA and regional records. Mechanism: Unknown.
- Mechanism
- Unknown
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Alaunos Therapeutics's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Alaunos Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Alaunos Therapeutics in public FDA and regional records.